The management may be an issue, but that still doesn't explain why investors play down a positive occurrence. Something just not right about that. Almost sounds like manipulation. Just my opinion!
They could invent the proverbial "cure for cancer" and the stock would still go down. When will they throw out Sir Andrew and his worthless cronies and get some real leadership? In the mean time, I'm sure the yearly bonuses are extra generous for the incompetent upper management. Criminal...
some news you would never know from yahoo unless you google the co:Wellbutrin class action suit against gsk was dismissed couple days ago.
"Glaxo Asthma Drug Clears Key Hurdle in Europe
BY Dow Jones & Company, Inc.
— 11:47 AM ET 09/24/2015
LONDON--GlaxoSmithKline PLC's ( GSK ) [GSK.LN] new severe-asthma medicine has received a positive opinion from the scientific committee of the European Medicines Agency for use in adults, clearing a key hurdle towards gaining marketing approval in Europe.
Yet, stock price still goes down.
I think the "Special Dividend" is only special because it will find its way into the bonus payments of the very "Special" idiots who are driving this stock into the toilet. How can GSK keep rewarding the incompetent management while the shareholders are continuously losing their shirts as the stock price plummets? The rich get richer...
Ultimate Stock Alerts has been killing it lately. I just made 57% over their last two plays. I know this sounds like a scam but they only alert NYSE and Nasdaq (no pennies) so there is actually money to be made
How much more are we expected to put up with this guy's incompedence?
Plain and simple. We need new leadership.
I'm tired of lower lows everyday.
On May 10, 2013 the U.S. Food and Drug Administration (FDA) approved BREO® ELLIPTA® as an inhaled long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations. In July 2013, BREO® ELLIPTA® was also approved in Canada for the long-term once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema, and to reduce exacerbations of COPD in patients with a history of exacerbations. BREO® ELLIPTA® is not indicated for the relief of acute bronchospasm or the treatment of asthma in the U.S. and Canada.
PS: It's also approved in the EU and Japan.
I know that seems small but you cannot assume that the 12.2% reduction in death( which is actually a huge positive) isn't due just to some random factor...but duh...COPD is a terminal illness....not to mention the other high rates of other illness in this population.....just set the bar too high!